LXEO
Lexeo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.28
+5.31%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.22
From 52W high−69.19%
Volume725587.00
Market cap$268.70M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.22
From 52W high
−69.19%
Volume
725587.00
Market cap
$268.70M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
51.5
MomentumView details →
1D Return
+5.31%
YTD Return
−67.42%
SummaryUpdated Jun 1, 2026
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical-stage genetic medicine company founded in 2017 and headquartered in New York, New York. The company went public in November 2023 and focuses on developing gene therapies for both hereditary and acquired diseases. Lexeo operates in the biotechnology sector, specifically targeting genetic disorders through advanced gene therapy approaches using adeno-associated virus (AAV) vectors.
Similar companies
Latest newsMore news →
Lexeo Therapeutics announced that it will present multiple presentations at the American Heart Association, Inc. Scientific Sessions 2026 and the International Congress for Ataxia Research 2026 in November.2d agoLexeo Therapeutics announced that an abstract on its LX2006 gene therapy has been accepted for oral presentation at the International Congress of Parkinson's Disease and Movement Disorders 2026, to be held October 4-8, 2026 in Seoul, Korea.34d ago